For example, researchers have noted a significant increase in the ALC of patients with human epidermal growth factor receptor 2 (HER2)-positive A/MBC after one cycle of trastuzumab emtansine treatment, or dissimilar changes in the ALC and NLR during the treatment with eribulin and bevacizumab among patients with A/MBC or non-small cell lung cancer, respectively [6, 20, 21]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.